Personalized Medicine in Prostate Cancer: From Diagnostic to Therapy

This course will be published in February 2026.

Radiolabelled prostate-specific membrane antigen (PSMA) is increasingly used in imaging and treatment of prostate cancer. PSMA-directed radionuclide therapy is an efficacious new treatment option in patients with metastatic castration-resistant prostate cancer (mCRPC) and beyond. The online course will cover the spectrum of radiolabelled PSMA tracers, techniques related to PSMA imaging, from diagnosis to therapy, with lectures, interactive case discussions, and relevant information for clinical practice.

PSMA PET-CT imaging- science and practice: 

• To provide an overview of clinical applications, normal biodistribution, variants, pitfalls and artefacts in PSMA PET-CT 
• To learn how to report PSMA PET-CT scans in primary staging and recurrence

Radionuclide PSMA therapy-science and practice (177Lu-PSMA therapies):

• To gain knowledge on PSMA patients selection, management of common clinical challenges in implementing and delivering of radionuclide therapies, side effects and their management
• To discuss current evidence and trends related to 177Lu-PSMA therapies 
• To learn about new or emerging targets and radioisotopes for Prostate cancer management

General nuclear medicine specialists, residents, radiologists, healthcare specialists who want to update their knowledge on molecular imaging and radionuclide therapy of prostate cancer including theranostics.